Search

Learn how MSK Direct — one of the nation's largest employer cancer benefits programs — made it easier for Steve Harrold to travel from Massachusetts to MSK for treatment days after a throat cancer diagnosis.

… Friday, March 28, 2025 Steve Harrold felt an immediate sense of dread as he watched the technician’s eyes widen during an image-guided scope of his throat. “I could tell that what she was looking at was not good,” he recalls. Steve had been experiencing slight difficulty swallowing, which he mentioned

Obtenga información sobre cómo MSK Direct, uno de los programas de beneficios oncológicos para empleadores más grandes del país, facilitó que Steve Harrold viajara desde Massachusetts a MSK para recibir tratamiento pocos días después de su diagnóstico de cáncer de garganta.

… Friday, March 28, 2025 Steve Harrold sintió una inmediata sensación de pánico al ver cómo se abrían los ojos de la técnica mientras le revisaba la garganta con un endoscopio guiado por imágenes. “Me di cuenta de que lo que estaba viendo no era algo bueno”, recuerda. Steve había sentido una leve dificultad

Memorial Sloan Kettering Cancer Center today announced that Shakeeb Akhter has joined MSK as its new Chief Digital Officer.

… Wednesday, May 20, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced that Shakeeb Akhter has joined MSK as its new Chief Digital Officer (CDO). In this role, Akhter will be responsible for the overall design and execution of MSK’s digital strategy.  Akhter joins MSK following a distinguished

The FDA has approved zenocutuzumab (Bizengri®) for adults with advanced, unresectable, or metastatic cholangiocarcinoma driven by a molecular change called an NRG1 gene fusion, based on a trial led by an MSK investigator.

… Wednesday, May 20, 2026 Cancer of the bile duct, called cholangiocarcinoma , is a rare, aggressive type of tumor in the liver that has a notoriously poor prognosis. But a newly approved drug will give patients another option to treat cancer that is inoperable, has spread, and is caused by a particular

The FDA has approved trastuzumab deruxtecan (T-DXd, Enhertu) for treating early-stage, HER2-positive breast cancer based in part on clinical research led by MSK breast medical oncologist Shanu Modi, MD.

… Friday, May 22, 2026 A drug that has already transformed care for metastatic HER2-positive and HER2-low breast cancer has now been approved by the U.S. Food and Drug Administration (FDA) to treat HER2-positive patients with early-stage disease. On May 15, 2026, the FDA extended approval for trastuzumab

Learn how a new MSK treatment approach preserves patients' noses while effectively treating nasal cavity cancer.

… Friday, March 20, 2026 Kevin Tougher never imagined a small growth in his nose would threaten his life.  A 39-year-old husband and elementary school principal, he and his wife, Maria, were getting ready to start a family. He discounted the lump as something a local ear, nose, and throat specialist would

New MSK research provides structural insights into how cancer cells thwart targeted RAS therapies; uncovers promising combination therapies for a rare childhood brain tumor; uses organoids to provide important clues about what drives pancreatic cancer; takes aim at appendix cancer with new laboratory models; and a develops a new precision tool for targeting cancer's energy factory.

… Tuesday, May 26, 2026   New research from Memorial Sloan Kettering Cancer Center (MSK) provides structural insights into how cancer cells thwart targeted RAS therapies; uncovers promising combination therapies for a rare childhood brain tumor; uses organoids to provide important clues about what drives